Welcome to the UPF Digital Repository

Dabrafenib in an elderly patient with metastatic melanoma and BRAF V600R mutation: a case report.

Show simple item record

dc.contributor.author Casadevall Aguilar, David
dc.contributor.author Vidal Barrull, Joana
dc.contributor.author Gallardo Hernández, Fernando
dc.contributor.author Zuccarino, Flavio
dc.contributor.author Arumí, Montserrat
dc.contributor.author Dalmases Massegú, Alba, 1982-
dc.contributor.author Bellosillo Paricio, Beatriz
dc.contributor.author Montagut Viladot, Clara
dc.date.accessioned 2016-07-19T11:36:04Z
dc.date.available 2016-07-19T11:36:04Z
dc.date.issued 2016
dc.identifier.citation Casadevall D, Vidal J, Gallardo F, Zuccarino F, Arumí-Uría M, Dalmases A. et al. Dabrafenib in an elderly patient with metastatic melanoma and BRAF V600R mutation: a case report. J Med Case Rep. 2016 Jun 2;10(1):158. doi: 10.1186/s13256-016-0953-0
dc.identifier.issn 1752-1947
dc.identifier.uri http://hdl.handle.net/10230/27091
dc.description.abstract BACKGROUND: Approximately 50 % of malignant melanomas harbor activating point mutations in the BRAF gene. Typically, these mutations result in the substitution of the amino acid valine at codon 600 of the gene, and 90-95 % of mutations are either BRAF (V600E) or BRAF (V600K). Specific BRAF inhibitors such as dabrafenib and vemurafenib are the mainstays of treatment in patients with metastatic BRAF-mutant malignant melanomas. The third most common BRAF mutation is V600R, which also leads to increased BRAF signaling. Although evidence exists about the activity of dabrafenib and vemurafenib in patients with the BRAF (V600R) mutation, these patients have been systematically excluded from recent trials with targeted therapies. CASE PRESENTATION: Here, we report the positive results in terms of survival and quality of life obtained with dabrafenib in an 80-year-old Caucasian male patient with a Charlson Comorbidity Index of 8 diagnosed with metastatic malignant melanoma harboring the BRAF (V600R) mutation. Our patient was treated with dabrafenib for 7 months with minimal toxicity. We also report exploratory analyses of circulating tumor DNA during targeted treatment. Interestingly, the mutation was not detected after starting treatment and became detectable before radiological disease progression. CONCLUSIONS: Our report suggests that (1) a relevant benefit can be obtained with a BRAF inhibitor in real-world patients with a malignant melanoma harboring a BRAF (V600R) mutation, and that (2) circulating tumor DNA detection might be of help in assessing tumor burden in everyday clinical practice. The results reported here should encourage the inclusion of patients with BRAF (V600R)-mutated malignant melanomas in future prospective clinical trials with BRAF inhibitors.
dc.format.mimetype application/pdf
dc.language.iso eng
dc.publisher BioMed Central
dc.rights © 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
dc.rights.uri https://creativecommons.org/licenses/by/4.0/
dc.subject.other Melanoma
dc.subject.other Regulació genètica
dc.title Dabrafenib in an elderly patient with metastatic melanoma and BRAF V600R mutation: a case report.
dc.type info:eu-repo/semantics/article
dc.identifier.doi http://dx.doi.org/10.1186/s13256-016-0953-0
dc.rights.accessRights info:eu-repo/semantics/openAccess
dc.type.version info:eu-repo/semantics/publishedVersion

This item appears in the following Collection(s)

Show simple item record

Search DSpace

Advanced Search


My Account


Compliant to Partaking